Hikvision Challenges FCC Rule Tightening Restrictions on Chinese Telecom Equipment 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Germany’s Economic Recovery Slows as Trade Tensions and Rising Costs Weigh on Growth 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Eli Lilly’s Inluriyo Gains FDA Approval for Advanced Breast Cancer Treatment 
EU Prepares Antitrust Probe Into Meta’s AI Integration on WhatsApp 
Proxy Advisors Urge Vote Against ANZ’s Executive Pay Report Amid Scandal Fallout 
FDA Lifts REMS Requirement for CAR-T Cell Cancer Therapies 
Australia’s Economic Growth Slows in Q3 Despite Strong Investment Activity 
SpaceX’s Starship Completes 11th Test Flight, Paving Way for Moon and Mars Missions 
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 
USPS Expands Electric Vehicle Fleet as Nationwide Transition Accelerates 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
Major Drugmakers Slash U.S. Prices and Sell Directly to Patients Amid Trump’s Push for Affordable Medicines 
Fujirebio Holding is now doubling down on developing blood tests to detect Alzheimer’s against which blockbuster therapy is expected soon.
The tiny Tokyo-based diagnostics firm, a unit of H.U. Group Holdings, which has a market value of $1.2 billion, developed the first US-approved spinal fluid test for Alzheimer’s.
According to Goki Ishikawa, the CEO of Fujirebio, the firm is boosting its lineup of reagents used to detect Alzheimer’s biomarkers in blood tests. It aims to file these tests for approval in the US as early as 2023.
Ishikawa said that the lineups offered by industry leaders are still limited, so they are rushing to create a solid lineup of tests.
